% | $
Quotes you view appear here for quick access.

ArQule Inc. Message Board

  • stev_26_2000 stev_26_2000 Jan 11, 2012 9:34 PM Flag

    Arqule at 16th JFCR-ISCC January 25th and 26th

    News January 25th or 26th? Maybe Arqule will take the opportunity to announce the HCC results here at the 16th JFCR-ISCC conference. Two presentations that include ARQ-197 are as follows:

    1) Haruyasu Murakami (Shizuoka Cancer Center)

    The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase 1 trial in Japanese patients with metastatic solid tumors

    2) Brian Schwartz (Arqule Inc)

    Discovery and Development of Tivantinib, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Solid Tumors.


1.82+0.04(+2.25%)Jun 28 4:00 PMEDT